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  Tirapazamine (TPZ) is an experimental prodrug for the treatment of various human cancers. TPZ shows
its cytotoxicity selectively in the solid tumors. TPZ derives its medicinal activity by inducing DNA damage in
poorly oxygenated tumors. Selective bioreductive enzymatic metabolism of TPZ in tumor cells leads to
radical intermediates, which primarily contribute oxidative DNA damage.  The nature of radical
intermediates responsible for DNA damage is still a matter of debate. At the same time, there is an ongoing
effort to prepare TPZ analogues as potential new antitumor agents. Thus, there is immediate need for the
development of synthetic methods for the preparation of TPZ analogues. To address these problems, we
have synthesized a series of heterocyclic N-oxide compounds which are structurally similar to antitumor
agent TPZ.  We have discovered some of the compounds damage DNA under bioreductive hypoxic
conditions, which are characteristics of solid tumors. We reinvestigate the mechanism of TPZ action, and
our data support the release of a hydroxyl radical from activated TPZ is responsible for DNA damage. This
information is critical to our understanding of the effect of anticancer agent TPZ on various solid tumors.  In
addition to this work, we have discovered for the first time the chemistry of the benzotriazine scaffold as a
hypoxia-selective fluorescent probe. This finding with the aid of technology may be useful in facilitating
hypoxia-directed imaging in cancer therapy.  
